



Saving lives of children  
with cancer through  
excellence in research,  
medical care, and  
education.

*This page is intentionally left blank*

## Content Page

Topic:	Page Number
About VIVA	3
Message from the Chairman	6
<b>VIVA's Projects:</b>	
VIVA-NUS Childhood Cancer Programme	7
VIVA-University Children Cancer's Centre (vuc <sup>3</sup> )	7
VIVA-Goh Foundation Professorship in Paediatric Oncology	7
Mrs. Lee Kong Chian Chair in Advanced Cellular Therapy	8
VIVA-NUS Centre of Translational Research in Acute Leukaemia (CENTRAL)	9
VIVA-KKH Paediatric Brain and Solid Tumour Programme	10
<b>Sharing Knowledge:</b>	
Continuing education for medical professionals:	
VIVA Education webinars	11
VIVA-ASIA Rare tumour board meetings	15
<b>Efforts against the Coronavirus:</b>	
VIVA against COVID	16
VIVA Stay Home Packs	17
Gathering Communities	18
<b>VIVA's Partners:</b>	
AIA Christmas Fundraiser Campaign - SHARING THE LOVE	24
Online Giving	25
VIVA in the Press	26
<b>Finance Matters:</b>	
Financial Statements	27
<b>VIVA's Internal Code and Key Members:</b>	
Code of Governance	36
Board of Directors	38
External Advisory Board	40
<b>Thank You</b>	42

The VIVA Foundation for Children with Cancer was incorporated in Singapore on 6 February 2006 as Public Company Limited by Guarantee. It was registered under the Charities Act on 25 April 2006, with Institution of a Public Character (IPC) status.

---

UEN:	200601578E
Charity Registration No.:	01961
IPC Effective Period:	25 April 2006 – 14 May 2021
HEF Registration Number:	HEF 0105/G
Registered Address:	8 Sinaran Drive #03-01 Novena Specialist Center Singapore 307470
Chairman:	Mrs Jennifer Yeo (Mdm Leong Lai Peng)
Auditors:	Moore Stephens LLP
Bankers:	Citibank Singapore Ltd DBS Bank Ltd Oversea-Chinese Banking Corporation Ltd United Overseas Bank Ltd

---

### FUNDING SOURCES

VIVA Foundation is financially supported by donations from members, donors and government grants.

### VOLUNTEERING

VIVA Foundation is open to the public for participation in its charitable activities in aid of children with cancer.

### STAFFING

As at 31 December 2020, there are four (4) full-time staff employed by VIVA Foundation.



## OBJECTIVES

To help cure children with cancer so they can achieve the full potential of their lives by:



**Partnering and funding scientists and doctors** in key projects and clinical research



**Supporting institutions** to provide optimum facilities and level of care



**Empowering doctors, nurses, and care-providers** through training and knowledge-sharing



## MESSAGE FROM THE CHAIRMAN



VIVA Foundation for Children with Cancer (VIVA) was established in 2006 to focus on saving the lives of more children with cancer through improving research, medical care and education. Since its creation 15 years ago, through the support and generosity of our donors and supporters, VIVA has been able to develop programs and initiatives in order to help children with cancer. Cutting-edge research work and improved care is vital in not only saving children but also in minimising late-life effects due to early-life treatment. This way, more children will not only be able to overcome their cancer, but also go on to achieve the full potential of their lives.

As we celebrate our 15<sup>th</sup> anniversary in the year 2021, we are also excited to launch our Life Program, which will help the children achieve and reach the very best versions of themselves, unhindered by the shadows of cancer. Our Life Program hopes to draw from the best in Integrative Medicine to give the children a new start in life so that they can look forward to long, healthy and happy lives after the end of treatment.

This has been a very tough year for all of us, with the world being crippled by the effects of the Coronavirus. We've had to live through tough economic times while our brave medical workers are in the frontlines fighting this pandemic, and for that I wish to extend a thank you to everybody who has contributed to the fight against the virus.

We want to thank you for being a part of our journey in saving the lives of as many children as we can and look forward to your continued support as we press on towards our goal.

A handwritten signature in black ink that reads "Jennifer Yeo". The signature is fluid and cursive, with the first name and last name clearly distinguishable.

Jennifer Yeo  
Executive Chairman and Founder  
VIVA Foundation for Children with Cancer  
3 March 2021

## VIVA-NUS CHILDHOOD CANCER PROGRAMME

### VIVA-UNIVERSITY CHILDREN CANCER'S CENTRE (VUC<sup>3</sup>)

The VIVA-University Children's Cancer Centre (VUC<sup>3</sup>) is VIVA's first childhood cancer centre of excellence. The VUC<sup>3</sup> provides a comprehensive childhood cancer treatment programme with capabilities of advanced cellular therapies and right siting of care with a 16-bed Day Therapy Centre for chemotherapy. It is housed at the National University Hospital (NUH).

VUC<sup>3</sup> was built in 2008 and funded by VIVA through its donors, such as the Lee Foundation and Tote Board.

Together with the Goh Foundation and Children's Cancer Foundation translational clinical research funding, VUC<sup>3</sup> has the capability to handle increasingly complex cases of childhood cancer from both Singapore and the surrounding region.

In 2020, the VUC<sup>3</sup> continued its mission to provide excellent medical care for children with cancer, with 558 inpatient admissions and 6762 outpatient therapies. Specialists at the VUC<sup>3</sup> also conducted 8 CAR-T infusions, 20 bone marrow transplants, and 6 NK therapies over the course of the year.

#### MEDICAL CARE (2020)

558	Inpatient admissions
6762	Outpatient therapies
20	Bone marrow transplants
6	NK therapies

### VIVA-GOH FOUNDATION PROFESSORSHIP IN PAEDIATRIC ONCOLOGY



A/Prof. Allen Yeoh

Associate Professor Allen Yeoh from the National University Singapore was appointed the VIVA-Goh Foundation Associate Professor in Paediatric Oncology in November 2012.

The professorship was created to advance paediatric oncology in strategic areas of childhood leukaemia, sarcoma, and childhood cancer survivorship.

It has also enabled Assoc Prof Yeoh to better the cure rates of children that suffer through childhood cancer in Singapore and Asia through clinical research and clinician training.

In 2020, he has been actively involved in the International Academic Community Service where, as a member of the St. Jude Global Alliance, helps to understand the awareness and use of the World Health Organization (WHO) recommendations for essential diagnostics and define what actions are needed to access to diagnostics for children with cancer beyond the reach of facility, community and country.

He is also assisting in the Asian Childhood Cancer Alliance (ACCA) in 2020 in trying to find better cures and better futures for children as part of their vision.

#### International Academic Community Service

## MRS LEE KONG CHIAN CHAIR IN ADVANCED CELLULAR THERAPY



*Dr. Dario Campana*

VIVA began the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy with the support of the Lee Foundation, which supports renowned expert Professor Dario Campana and his team at the National University Hospital of Singapore to conduct research on cell-based therapy and clinical trials for breakthroughs in cancer treatment.

One such treatment is the experimental CAR-T cellular immunotherapy which was developed by the Chair Professor Campana, who recently won the President's Technology Award for his work in using immune cells for the treatment for cancer.

Dr Dario's work in using CAR-T Cells in the treatment of both children and adults are highly encouraging. These results could usher in a new era in ALL treatment.

Dr Campana and his team plan to conduct therapy trials for up to 100 patients in the next 5-10 years.

The promising work done under Mrs Lee Kong Chian Chair has also since unlocked over \$6M of additional research funding from the NCIS Cancer Centre, the Goh Foundation, the Lee Foundation, and the Children's Cancer Foundation, amongst others—ensuring that we can all continue the development of new cures that would enable doctors to save more lives for children with cancer.

VIVA is grateful for this on-going collaboration which has been on-going since the Chair's inception in 2013 and would also like to thank all our donors for their contributions to this programme.

Total funds raised for VIVA-University Children's Cancer Centre, Mrs Lee Kong Chian Chair, VIVA-Goh Foundation Professorship and VIVA Education and Research Fund.

**\$ 54,906,326\***

\* This figure includes funds raised by: VIVA and our respective partners





## VIVA-NUS CENTRE OF TRANSLATIONAL RESEARCH IN ACUTE LEUKAEMIA (CentRAL)

From left: Mrs Jennifer Yeo, Prof. Tan Chorh Chuan, Mr Ho Cheng Huat

### ACCREDITATION

- ✓ Laboratory tests accredited by the Singapore Accreditation Council as fulfilling base requirements for ISO 15189
- ✓ First university-based laboratory in Singapore to receive SingClass accredited laboratory mark

### TOTAL FUNDS RAISED FOR THIS PROGRAMME IN 2020

\$ 1,300,000

### TOTAL FUNDS RAISED FOR THIS PROGRAMME (2020)

\$ 8,026,692\*

\* This figure includes funds raised by: VIVA and our respective partners

In 2014, VIVA set up the **VIVA-NUS Centre for Translational Research in Acute Leukaemia (CentRAL)** in collaboration with the National University of Singapore. CentRAL was established to aims to further research on paediatric acute leukaemia, the most common form of childhood cancers. Ultimately, it serves to improve cure rates of children and adults with acute lymphoblastic leukaemia (ALL).

The facility is led by VIVA-Goh Foundation Assoc Prof Allen Yeoh and Mrs Lee Kong Chian Chair Prof Dario Campana from the NUS School of Medicine.

Since its inception, CentRAL was able to conduct some 2,554 molecular tests for childhood cancer patients. The tests enabled doctors to better determine the best levels of treatment, with 80% of patients receiving less chemotherapy, less side effects, improving their chances for cure.

In 2020, CentRAL was awarded the Singapore Accreditation Council SINGCLASS Accredited

Laboratory Mark—the first university-based laboratory in Singapore to do so—enhancing its credibility and assuring the public that services are conducted in line with globally-recognised standards. Aside from this, six laboratory tests developed by CentRAL were also accredited by the SAC as fulfilling ISO 15189 requirements.

Since VIVA's establishment in 2006, we have been supporting the Malaysia-Singapore Acute Lymphoblastic Leukaemia (ALL) Study. CentRAL's molecular testing in children with ALL is the world's first clinical trial incorporating the IKZF1 gene risk assignment as identified from the study. This has resulted in an improvement in cure rates and delivered one of the best ALL treatment outcomes in the world—a drop in relapse rates from 30.4% to 13.5%. CentRAL will continue this study in 2020 for the next five years, after successfully clinching additional funding from the highly competitive National Medical Research Council grant in 2020.

## VIVA-KKH PAEDIATRIC BRAIN AND SOLID TUMOUR PROGRAMME

Despite advances in the treatment of paediatric cancers, outcomes for most childhood solid tumours remain inferior to blood cancers.

Established in 2015, the **VIVA-KKH Paediatric Brain and Solid Tumour Programme** is a collaborative clinical and research partnership between VIVA, KK Women's and Children's Hospital (KKH), and St. Jude Children's Research Hospital to seek advancements in childhood brain and solid tumours by improving clinical care, translational research, education, and leveraging the expertise and strength of partner institutions.

Even though the pilot programme ended in 2018, the advancements made during the collaboration continues to benefit a wider public. New diagnostic tests were developed and rolled out across Singapore and the region. Patients received improved medical care through a multi-disciplinary brain tumour clinic providing a one-stop outpatient services,

which continues to run today.

Up to end 2020, net research output of the Programme has amounted to 53 publications in peer-reviewed journals and 43 presentations to date. 16 competitive grants totalling \$3.4 million were brought in to supplement the funding from the Programme.

Patients now have more access to several international multi-centre paediatric solid tumour clinical trials that have opened at KK Women's and Children's Hospital.

5 doctors from regional low- and middle-income countries benefited from the exchange programme started in 2019. These included 4 observerships in paediatric pathology and 1 fellowship in paediatric surgical oncology, training alongside the SingHealth clinical team and engaging in research and education projects.

The PBSTA Programme, which began in 2014, has since grown in its awareness and funds in support of childhood cancer. A student-led initiative by Duke-NUS Medical School, VIVA has been invited to attend the Paediatric Brain Solid Tumour Awareness Day yearly.

In 2020, PBSTA was held at Marina Barrage and the students put together a day of activities for childhood survivors of brain and solid tumours.

Our Director, Ms. Shulamite Khoo, was invited to be the Guest-of-Honour at the event where she assisted the volunteers in raising awareness. Present were members of the Medical Board, KKH and Assoc Prof David Low, Head of Neurosurgery and Senior Consultant at the National Neuroscience Institute.

VIVA thanks Duke-NUS Medical School, Pirelli Asia Singapore Pte Ltd, Porsche Club Singapore and Yakult Singapore for supporting this event.

### MEDICAL CARE AND ACHIEVEMENTS

**78** New patients for Brain and Solid Tumours

**43** Presentations

**53** Publications

### TOTAL FUNDS RAISED FOR THIS PROGRAMME

**\$ 26,208,937\***

\* This figure includes the seed funding of \$8,200,000 raised by VIVA and additional funds from partners and government matching.



Our partners joined by Ms Shulamite Khoo

**Paediatric Brain and Solid Tumours Awareness Day**

23 Mar 2020

## CONTINUING EDUCATION FOR MEDICAL PROFESSIONALS: VIVA EDUCATION WEBINARS



### VIVA 2020 EDUCATION WEBINARS IN NUMBERS

**900+** Participants

**36** Countries

**9** Webinars

In the wake of the COVID-19 pandemic, VIVA's annual 14<sup>th</sup> St.Jude-VIVA Forum on Paediatric Oncology was cancelled in the interest of safety for all medical professionals attending, staff, and patients.

However, as part of VIVA's mission to ensure that medical education continues even though the pandemic has made face-to-face learning sessions impossible, we began to organise VIVA Education Webinars in partnership with the medical community, and supporters such as Bayer and Amgen.

### VIVA WEBINARS IN 2020

#### NTRK Fusions in Paediatric Cancers 5 March 2020

Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions are an emerging category of genetic alterations that occur in a broad range of both paediatric and adult cancers. Identification of NTRK gene fusions is important because of recent FDA approval of tumour-agnostic targeted therapeutics against cancers with such gene alterations.

In this webinar, pathologist Adj Assoc Prof Kenneth Chang (KKH) discussed the challenges and approaches of diagnosing such cancers using both conventional and molecular pathology techniques in the clinical setting. Paediatric oncologist Dr Prasad Iyer described a patient care journey. Adult oncologist and researcher Assoc Prof Daniel Tan provided an update on local clinical trials of NTRK inhibitors.



#### Speakers

**Adj Assoc Prof Kenneth Chang**, KK Women's and Children's Hospital (KKH), Singapore



The webinar was moderated by paediatric oncologist Dr Soh Shui Yen.

*This webinar was supported with an educational grant from Bayer South East Asia.*

## The ALL Genome in 2020: Implications for Diagnosis and Treatment

22 September 2020

The webinar with renowned oncologists Prof Charles Mullighan (St Jude Children's Research Hospital, USA) and Assoc Prof Allen Yeoh (NUH) provided an overview of the current molecular taxonomy of acute lymphoblastic leukaemia.

This webinar reviewed the currently accepted genetic subtypes, the type of genetic alterations that define each, associations with disease behaviour, age, and prognosis. Implications for mechanisms of leukemogenesis and therapeutic intervention were also presented.

*This webinar was sponsored with an educational grant from Amgen.*

Dr Prasad Iyer, KKH  
Assoc Prof Daniel Tan, National Cancer Centre, Singapore

Chair  
Dr Soh Shui Yen, KKH



Speaker  
Prof Charles Mullighan,  
St Jude Children's Research Hospital, USA

Chair  
A/Prof Allen Yeoh, National University Hospital Singapore

## VIVA Asia Education Webinar Series

### Every LCH Child is Different: Unconventional Approaches to a Fascinating Disease

21 July 2020

The VIVA Asia Education Webinar Series brings together regional delegates from developing countries to discuss treatment, data management, and evaluation of outcomes for paediatric solid tumours and leukaemia. This Webinar Series continues the educational opportunities offered by the VIVA Asia Educational Day, which evolved from the pre-forum workshop at the annual St. Jude-VIVA Forum in Paediatric Oncology.

In this webinar, Prof TC Quah (NUH) shared his lifelong interest in LCH, as well as his experiences with this complex and challenging condition.

*This webinar was organised in partnership with the Asia Childhood Cancer Alliance and St Jude Global.*



Speaker  
A/Prof TC Quah, National University Hospital Singapore

Chair  
Dr Shweta Bansal, Sir HN Reliance Foundation Hospital and Research Centre, India

## VIVA Asia Bone Marrow Transplant Autumn School: Updates on HSCT for Childhood Leukaemia

22 August 2020

The most common diseases treated with allogeneic hematopoietic stem cell transplantation in children are acute leukaemias. With recent advances in transplant regimens and supportive care, the outcome of patients has steadily improved. In this webinar, Prof Wing Leung (KKH) discussed several controversial issues and outline some conceptual frameworks in transplants.

The main presentation by Prof Wing Leung (KKH) was followed by interactive case discussions with expert panel comprising Prof Wing Leung, Dr Pamela Lee (HKU), Assoc Prof Tan Poh Lin (NUH), moderated by Prof Hany Arifin (UMMC)

*This webinar was organised in partnership with the VIVA Asia Bone Marrow Transplant Consortium.*



Speaker  
Prof Wing Hang Leung, KK Women's and Children's Hospital (KKH), Singapore

Panellists



**A/Prof Tan Poh Lin**, National University Hospital Singapore  
**Dr Pamela Lee**, Hong Kong Children's Medical Centre

Chair

**Prof Hany Ariffin**, University of Malaya Medical Centre

### The ALL Landscape in 2020

22 September 2020

In this webinar, Professor Hiroto Inaba (St Jude Children's Research Hospital) discussed the optimal use of Immunotherapy agents in high risk ALL and how to reduce the relapse risk in such children.

Professor Vaskar Saha (University of Manchester) discussed the strategies of treating relapsed refractory ALL highlighting the lessons learnt from R3 and IntReALL trials. He also discussed how these strategies can be adapted in developing world to improve outcome in children who currently have poor prognosis without very advanced treatment facilities.

This webinar was chaired by Dr Rajat Bhattacharyya (KKH).

*This webinar is sponsored with an educational grant from Amgen.*



Speakers

**Prof Hiroto Inaba**, St Jude Children's Research Hospital, USA  
**Prof Vaskar Saha**, University of Manchester, UK

Chair

**Dr Rajat Bhattacharyya**, KK Women's and Children's Hospital, Singapore

### VIVA Asia Education Webinar Series

#### Current Concepts in the Biology and Treatment of Langerhans Cell Histiocytosis (LCH)

2 October 2020

Despite progress made in the treatment of LCH, disease reactivation rates remain above 30%, and standard second-line treatment is yet to be established. Treatment failure is associated with increased risks of death and long-term morbidity, including LCH-associated neurodegeneration. Early case series report promising clinical responses in patients with relapsed and refractory LCH treated with BRAF or MEK inhibitors, although potential for this strategy to achieve cure remains uncertain.

In this webinar, Dr Carlos Rodriguez-Galindo (St Jude Children's Research Hospital) discussed the latest research on Langerhans Cell Histiocytosis (LCH). With panellists A/Prof TC Quah (NUH), Dr Michelle Hermiston (UCSF), chaired by Dr Frances Yeap (NUH).

*This webinar was organised in partnership with the Asia Childhood Cancer Alliance and St Jude Global.*



Speaker

**Dr Carlos Rodriguez-Galindo**, St Jude Children's Research Hospital, USA

Panellists

**A/Prof TC Quah**, National University Hospital Singapore  
**Dr Michelle Hermiston**, University of California San Francisco, USA

Chair

**Dr Frances Yeap**, National University Hospital Singapore

### State-of-the-Art Immunotherapy in ALL

14 October 2020

Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies for ALL over the past decade. Renowned haematologists Prof Elias Jabbour (MD Anderson Cancer Centre, USA) and Dr Jae H Park (MSKCC, USA) provided an overview of the current innovative T cell-engaging approaches for ALL treatment. Chaired by Dr Lim Zi Yi (Mount Elizabeth Novena Hospital).

*This webinar was sponsored with an educational grant from Amgen.*



Speakers

**Prof Elias Jabbour**, MD Anderson Cancer Centre, USA

**Dr Jae H Park**, Memorial Sloane Kettering Cancer Center, USA

Chair

**Dr Lim Zi Yi**, Mount Elizabeth Novena Hospital, Singapore

### VIVA Asia Education Webinar Series

#### PET/CT in Paediatric Oncology

27 October 2020

In this webinar, Dr Arvind Kumar Sinha (NUH) spoke on the role of PET/CT in assessing a wide variety of pediatric malignancies, including lymphomas, soft-tissue, neuroendocrine tumors and bone sarcomas. With panelists Dr Soh Shui Yen (KKH), Dr Miriam Kimpo (NUH), Dr Tricia Alcasabas (PGH), chaired by A/Prof TC Quah.

*This webinar was organised in partnership with the Asia Childhood Cancer Alliance and St Jude Global.*



Speaker

**Dr Arvind Kumar Sinha**, National University Hospital Singapore

Panellists

**Dr Miriam Kimpo**, National University Hospital Singapore

**Dr Tricia Alcasabas**, Philippine General Hospital

**Dr Soh Shui Yen**, KK Women's and Children's Hospital Singapore

Chair

**A/Prof TC Quah**, National University Hospital Singapore

### VIVA Asia Education Webinar Series

#### Too Much of a Good Thing: Approach to Hemophagocytic Lymphohistiocytosis (HLH)

1 December 2020

In this webinar, Dr Michelle Hermiston (University of California San Francisco) tackled identifying HLH as a clinical syndrome that can be caused by multiple etiologies; explained the pathophysiology of HLH and its common manifestations; and described treatment modalities for newly diagnosed and refractory patients. With panellist A/Prof TC Quah (NUH), chaired by Dr Frances Yeap (NUH).

*This webinar was organised in partnership with the Asia Childhood Cancer Alliance and St Jude Global.*



Speaker

**Dr Michelle Hermiston**, University of California San Francisco, USA

Panellist

**A/Prof TC Quah**, National University Hospital Singapore

Chair

**Dr Frances Yeap**, National University Hospital Singapore


## VIVA ASIA RARE TUMOUR BOARD MEETINGS

---

### First VIVA Asia Rare Tumour Board Meeting 24 July 2020

The first VIVA Asia Rare Tumour Board Meeting commenced with attendees from Canada, China, Germany, Hong Kong, Singapore and USA.

The meeting is part of VIVA's commitment towards enabling doctors to work together on rare tumours. The session involved a case presentation a patient with DICER1 syndrome associated pelvic tumour was presented by Dr Joshua Chan, Prof KF To and Dr Amanda Kan from the Hong Kong Children's Hospital Oncology Team, followed by an in-depth discussion by several solid tumour experts from across the world.



#### Presenters

**Dr Joshua Chan**, Hong Kong Children's Hospital

**Prof To Ka Fai**, Hong Kong Children's Hospital

**Dr Amanda Kan**, Hong Kong Children's Hospital

#### Chair

**Prof Godfrey Chan**, Hong Kong Children's Hospital

---

### Second VIVA Asia Rare Tumour Board Meeting 4 Sept 2020

The second VIVA Asia Rare Tumour Board Meeting commenced with attendees from China, Germany, Hong Kong, Singapore, and USA.

The meeting included a case presentation on the Primitive Myxoid Mesenchymal Tumour of Infancy by Dr Eric Fu, Dr Derek Yau and Dr Ying-Lee Lam from the Hong Kong Children's Hospital Oncology Team, followed by an in-depth discussion by several solid tumour experts from across the world.



#### Presenters

**Dr Eric Fu**, Hong Kong Children's Hospital

**Dr Derek Yau**, Hong Kong Children's Hospital

**Dr Lam Ying-Lee**, Hong Kong Children's Hospital

#### Chair

**Prof Godfrey Chan**, Hong Kong Children's Hospital



## VIVA AGAINST COVID



Cancer does not stop, even in the midst of the Covid-19 pandemic. It has made things even harder for kids with cancer--with compromised immunities, they've had to stay home since the beginning of the outbreak. Unable to go to school, meet friends, and go outside due to heightened risks from childhood cancer. It's even more important for them to stay home and practice social distancing.

As a response to the pandemic, VIVA has rolled out several programmes with the support of several partners across Singapore to support households affected by childhood cancer--from activities to do at home, resources for staying healthy and well, to equipment needed for online learning.

VIVA wishes to thank partners, supporters, donors, and sponsors for enabling us to implement our VIVA Against COVID initiatives in aid of households affected by childhood cancer.

### VIVA WISHES TO THANK:

*Mr Sun Xi and Family  
Ms Shu Khoo and Family  
Mr George and Mrs Jennifer Yeo  
Dr Ravikumar Chinniah  
The Birthday Collective  
Spearling Events  
Be Kind SG  
Landmark Books  
Woods in the Books  
The Cocoa Trees  
Nalandaway Foundation  
Donors from Giving.sg  
BooksActually  
Engineering Good  
The Red Pencil Singapore  
Mr Tze Toh*





## VIVA STAY HOME PACK



### VIVA STAY HOME PACKS IN NUMBERS

115+

VIVA Stay Home  
Packs sent to  
Households

100+

VIVA Stay Home  
Packs sent through  
Hospitals

During the Covid-19 pandemic, kids with cancer are even more so unable to go to school, meet friends, go outside, due to heightened risks from childhood cancer.

VIVA put together the VIVA Stay Home Packs, which are filled with safety masks, treats, books, and fun activity sheets designed to support families affected by childhood cancer as they stayed at home during the Circuit Breaker period. The Stay Home packs were sent directly to households and through our partners at the VIVA-University Childhood Cancer Centre (VUC3) and at the KK Women's and Children's Hospital (KKH).

## EXTENDED OUTREACH



Being stuck at home is difficult. To complement the physical VIVA Stay Home Packs, a series of online-based components were pushed out to support households affected by childhood cancer with various activities to help cope during the COVID-19 pandemic.



**VIVA La Monday Morning**  
27 April 2020 / 4 May 2020

An online, interactive double session featuring artwork submissions from kids with cancer, interpreted live on air into music by VIVA volunteer, Singaporean pianist and artist, Tze Toh.



**VIVA Daily Tips**  
April-May 2020

A daily newsletter featuring resources on educational activities for kids to do during the Covid-19 Circuit Breaker period.



**VIVA x The Red Pencil Art Therapy Programme**  
April-May 2020

In partnership with The Red Pencil, families affected by childhood cancer to have eight sessions of art therapy.

*The VIVA-The Red Pencil Art Therapy Programme was implemented in partnership with The Red Pencil Singapore.*



**Computers Against COVID**  
June 2020

VIVA partnered Engineering Good's programme—Computers Against Covid—to distribute pre-loved, refurbished laptops to those affected by childhood cancer and would need the equipment for home and web-based learning during and after Singapore's Covid-19 circuit breaker phase.

VIVA wishes to thank Engineering Good for this partnership, and the Glover family who volunteered to deliver each laptop to every family that signed up for this programme!



---

## GATHERING COMMUNITIES

VIVA brings together communities from different walks of life in support of childhood cancer—from fun social activities for patients, survivors, and their families, to public awareness campaigns and fundraising drives to support VIVA’s mission to save more lives.



To celebrate Childhood Cancer Awareness Month in September, we worked with VIVA volunteer Chriscavin to highlight stories of strength and survival, filled with love and hope for the future, and to raise awareness on the challenges of childhood cancer not just for patients, but also on their families.

## Chris



Chris was a regular Secondary 4 student dealing with school, tuition, homework, and preparing for his O-Levels. That all changed when he was diagnosed with high-risk Acute Lymphoblastic Leukaemia at the age of 15.

Five years and two relapses later, Chris became Singapore's very first recipient of CAR-T cellular immunotherapy in 2018, under the VIVA-NUS Childhood Cancer Programme, led by VIVA-Goh Foundation Associate Professor Allen Yeoh and Mrs Lee Kong Chian Chair in Advanced Cellular Therapy Professor Dario Campana.

***I have lost years of my youth. I think it's important to focus on what you can control. Hardships are going to happen all the time and it's important to be able to focus on good things you can find out of the tough times."***

Two years later, Chris is doing well. "I was very fortunate to have been at the right time and the right place," he says, as it had been difficult to deal with several relapses over the course of his treatment. Today, he is looking forward to giving back to the community



## Ezri and Amy

At the tender age of two-and-a-half, Ezri was diagnosed with Acute Lymphoblastic Leukemia (ALL). She often fell sick, and despite going to many clinics, doctors were unable to figure out what was wrong. It was not until they rushed Ezri to the Children's Emergency centre at the National University Hospital that the doctors suspected she had leukemia, following her blood test.

Cancer posed new challenges not just for Ezri, but for the entire family. Aside from the challenges of treatment, it also meant being separated from her twin sister Ivey, while she was in the hospital. The family had to be extra careful not to get sick, with restrictions in diet and cleanliness to make sure Ezri remains healthy. For Ivey, it meant feeling lost and unloved.

As Ezri recovered, the family has since reunited and is closer than ever. "We cherish each other more than before," says Amy.

Four years later, both Ezri and Ivey have begun school—a big milestone for them both. "It's such a joy to see her go to school, make new friends, see her smile, and behave like a normal kid," says Amy, their mum. "Being normal is a joy in life."



***It's such a joy to see her go to school, make new friends, see her smile, and behave like a normal kid. Being normal is a joy in life.***

**—Amy, Ezri and Ivey's mum**



(1) Top: Ezri today is doing well, four years since her diagnosis; (2) Left: VIVA volunteer Chrisavin preparing to interview Amy (right), Ezri and Ivey's mum; (3) Left column: Ezri (right) with her twin sister Ivey are reunited!



When Yen Yen sent her son Darshan to the Emergency Room for persistent fever and body aches, little did they think it would be more serious than an infection. It turned out to be cancer.

Darshan was diagnosed with Acute Lymphoblastic Leukaemia (ALL) at the age of three. Until then, his life had been normal, and the cancer changed his entire life. The treatment journey proved difficult.



"It was very tough," his mom Yen Yen shares. "Because he was so young, he didn't understand what was going on. Whenever doctors and nurses came, he would begin to scream and cry, because whenever we touched him he would feel pain."

It was equally hard for the entire family to see him in distress. "Whenever he cried, we thought about how we could help alleviate his pain. We felt so helpless."

Today, Darshan is on the road to recovery, but that doesn't stop the worries for a relapse. For Yen Yen, she hopes that as Darshan is now better, he would be able to catch up with all the things he's lagged behind.

But most importantly she hopes the cancer doesn't come back. "Just like Darshan always tells me, I'm a normal boy again, so that's what I hope for."

***Whenever he cried, we thought about how we could help alleviate his pain. We all wished we could take away whatever he was going through. We couldn't do much. We felt so helpless.***

**—Yen Yen,  
Darshan's mum**



*1) Top: Darshan today at six years old; (2) Middle: Darshan visits the VIVA Hub*



***While there is a lot of acute care during cancer treatment, support drops off when treatment ends. This is why we believe support has to continue beyond treatment to make sure survivors are able to thrive, and live healthy, meaningful lives.***

**—Mrs Jennifer Yeo, VIVA Founder and Chairman**

Covid-19 has added to the challenges of families coping with childhood cancer. Along with many others, the pandemic has meant a lot of difficulties for Jane\*. This included losing her part-time job, which was her main source of income. As a single mother of three, and a caregiver of a child with cancer, she was devastated.

Through the VIVA Life Programme, VIVA brought together a community of amazing partners in support of Jane and her family. Kind-hearted donor, Mdm Lim Hwee Hwa, Mr Victor Lim and the Glover Family contributed assistance to help tide over the family's immediate needs, as well as Organisations such as the Order of the Knights of Malta, Food from the Heart, and Engineering Good were mobilised by VIVA to cover different needs—from furniture, to monthly groceries, or a refurbished computer for home-based learning.

“While there is a lot of acute care during cancer treatment, support drops off when treatment ends,” says VIVA Founder and Chairman Mrs Jennifer Yeo. “This is why we believe support has to continue beyond treatment to make sure survivors are able to thrive and live healthy, meaningful lives.”

*\*Not her real name*



AIA Singapore selected VIVA to be one of its beneficiary charities in 2020, which included several campaigns to spread the love to children battling cancer enabling Singaporeans to live healthier, longer, and better lives.

As part of their support for VIVA, AIA held a series of campaigns in support of VIVA, including a donation drive amongst their agents to pledge a donation for every policy signed, an internal staff Christmas donation drive, and a holiday merchandise campaign where proceeds went towards supporting the mission of VIVA.

Through the three campaigns, AIA was able to raise \$207,798 in aid of VIVA. We wish to thank AIA and its team for supporting our cause!



## ONLINE GIVING



VIVA thanks our generous individual donors who have contributed to support VIVA's mission via online platform Giving.sg! We also thank the following supporters who organised online fundraising campaigns in aid of VIVA.

---

### **Little Action that Goes the Long Way**

Sheron Tan

For her birthday, Sheron Tan raised \$1,276 to help bless more children who are suffering from childhood cancer and for them to live a better life.

---

### **In Loving Memory of Our Beloved Sister, Aunt (Kor Kor) Oh Kim Heo @ Teo Ah Tin**

Andy Teo and Family

The Teo Family raised \$2,890 to honour the memory of their Aunt, Oh Kim Heo, who passed away in 2020, and to support the development of life-saving treatment and medical care to improve life post-cancer.

## VIVA IN THE PRESS



- [Helping our neighbours in the war against childhood brain and solid tumours, one fellow at a time](#)  
(SingHealth, 20 Oct 2020)
- [Brain and Solid Tumours Amongst Children, Interview with Dr Amos Loh](#)  
(Health Matters, CNA 938, August 2020)
- [Covid-19 heroes: Activity kits bring joy to kids in need](#)  
(The Straits Times, Aug 2020)
- [Ching-Hon Pui, MD, receives Medal of Honor from the American Cancer Society](#)  
(EurekAlert, March 2020)
- [Partnership with China Prompts Change in Care for High-Risk Type of Leukemia](#)  
Newswise, Jan 2020

# STATEMENT OF FINANCIAL ACTIVITIES

For the Financial Year Ended 31 December 2020

INCOME	2020 S\$	2019 S\$
<b>Unrestricted General Funds</b>		
Income from generated funds		
- Voluntary income	1,908,983	2,359,931
- Investment Income	46,153	48,061
- Activities for generating funds	2,600	171,322
Income from charitable activities	273	515,548
Other Income	61,529	255
<b>TOTAL INCOME</b>	<b>2,019,538</b>	<b>3,095,117</b>
 <b>EXPENDITURES</b>		
Cost of generating funds		
- Cost of generating voluntary income	32,588	64,322
Charitable activities	1,329,072	1,602,505
Governance costs	918,969	878,438
<b>TOTAL EXPENDITURES</b>	<b>2,280,629</b>	<b>2,545,265</b>
 <b>Net income (expenditure)/income before tax expense</b>	<b>(261,091)</b>	<b>549,852</b>
 <b>Tax expense</b>	<b>-</b>	<b>-</b>
<b>Net (income) expenditure</b>	<b>(261,091)</b>	<b>549,852</b>
 Gross transfers between funds	<b>-</b>	<b>-</b>
<b>Net movement in funds</b>	<b>(261,091)</b>	<b>549,852</b>
 <b>Reconciliation of funds</b>		
Total funds brought forward	25,622,263	25,072,411
<b>Total funds carried forward <sup>(A)</sup></b>	<b>25,361,172</b>	<b>25,622,263</b>

Excerpted from the full Audited Financial Report 1 Jan 2020 to 31 Dec 2020, which will be attached separately to this Annual Report.

# STATEMENT OF FINANCIAL POSITION

For the Financial Year as at 31 December 2020

	2020 S\$	2019 S\$
<b>Non-Current Assets</b>		
Property and Equipment	19,447,432	19,974,062
<b>Current Assets</b>		
Inventories	2,264	
Other receivables and prepayments	237,932	157,839
Cash and cash equivalents	5,772,650	5,594,499
	6,012,846	5,752,338
<b>Current Liabilities</b>		
Accrued Expenses	566	6,825
Deposits Received	50,014	50,014
Other payables	48,526	47,298
	99,106	104,137
<b>Net Current Assets</b>	5,913,740	5,648,201
<b>Total Assets Less Current Liabilities</b>	25,361,172	25,622,263
<b>Funds of Charity</b>		
<u>Unrestricted Funds</u>		
General funds <sup>(A)</sup>	25,361,172	25,622,263
<b>TOTAL CHARITY FUNDS</b>	25,361,172	25,622,263



## STATEMENT OF CASH FLOW

For the Financial Year Ended 31 December 2020

	2020	2019
	S\$	S\$
<b>Cash Flows from Operating Activities</b>		
- Net income/(expenditure) before tax expense	(261,091)	549,852
Adjustments for:		
- Depreciation of property and equipment	528,749	528,043
- Interest income	(46,153)	(48,061)
<b>Operating cash flows before changes in working capital</b>	221,505	1,029,834
- Other receivables and prepayments	(80,093)	22,775
- Inventories	(2,264)	-
- Accrued expenses	(6,259)	5,023
- Other payables	1,228	26,298
- Deposits received	-	(2,348)
<b>Net cash flows generated from / (used in) operating activities</b>	134,117	1,081,582
<b>Cash Flows from Investing Activities</b>		
- Purchase of equipment	(2,119)	(14,394)
- Interest received	46,153	48,061
<b>Net cash flows generated from investing activities</b>	44,034	33,667
<b>Net increase/(decrease) in cash and cash equivalents</b>	178,151	1,115,249
<b>Cash and cash equivalents at the beginning of the year</b>	5,594,499	4,479,250
<b>Cash and cash equivalents at the end of the year (Note 16)</b>	5,772,650	5,594,499

## COMMUNITY PARTNERSHIP

### (Other Charity Funds)

The Charity held donation drives to raise funds for specific projects. As at 31 December 2020, a total funds of S\$80,273,867 (2019: S\$78,172,993) was raised by the Charity with a government matching grant of S\$45,066,578 (2019: 45,065,588)

The details of the funds are divided into three categories as follows:

- specific donations received under the Charity as donation income;
- specific donations co-funded by the Charity and Community Partners; and
- specific donations paid directly to the Community Partners as beneficiaries.

Except as disclosed in Note 20, the details of funds which the donations and the amounts expended below are not reflected in the financial statements of the Charity.

	Cumulative Funds raised as at 31 December 2020		Fund Balances as at 31 December 2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
<b>(A) Specific donations received under the Charity as donation income</b>				
Donated space (Note 20)	24,100,000	-	19,400,500	-
Available fund balance (Note 20)	9,798,490	-	5,960,672	-
VIVA-NUS CenTRAL (Note 23 A1)	8,026,692	-	1,793	-
VIVA-Mr Goh Hup Jin Fund (Note 23 A2)	1,300,000	-	1,300,000	-
Cancer Immunotherapy (Note 23 A3)	1,000,000	-	-	-
Subtotal	44,225,182	-	26,662,965	-
<b>(B) Specific donations co-funded by the Charity and Community Partners</b>				
<b>VIVA-KKH Childhood Brain and Solid Cancers Programme (Note 23 B1)</b>	13,257,349	12,951,588	5,017,997	12,950,000
<b>(C) Specific donations paid directly to the Community Partners as beneficiaries</b>				
<b>NUS Children Cancer Centre Fund (Note 23 C1)</b>	2,488,622	4,084,512	1,475,950	2,530,639
<b>NUH Health Research Endowment Fund (Note 23 C2)</b>	7,237,009	3,000,000	2,294,228	3,000,000
<b>VIVA Paediatric Oncology Fund (Note 23 C3)</b>	12,285,705	23,743,824	1,343,039	13,719,636
<b>VIVA Education and Research Fund (Note 23 C4)</b>	780,000	1,286,654	-	776,215
Subtotal	22,791,336	32,114,990	5,113,217	20,026,490
Total	80,273,867	45,066,578	36,794,179	32,976,490

# COMMUNITY PARTNERSHIP

(Other Charity Funds)

	Cumulative Funds raised as at 31 December 2019		Fund Balances as at 31 December 2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
<b>(A) Specific donations received under the Charity as donation income</b>				
Donated space (Note 20)	24,100,000	-	19,882,500	-
Available fund balance (Note 20)	9,333,545	-	5,739,763	-
VIVA-NUS CenTRAL (Note 23 A1)	7,772,099	-	(217,610)	-
Cancer Immunotherapy (Note 23 A3)	1,000,000	-	-	-
Subtotal	42,205,644	-	25,404,653	-
<b>(B) Specific donations co-funded by the Charity and Community Partners</b>				
VIVA-KKH Childhood Brain and Solid Cancers Programme (Note 23 B1)	13,257,349	12,951,588	5,312,631	12,951,588
<b>(C) Specific donations paid directly to the Community Partners as beneficiaries</b>				
NUS Children Cancer Centre Fund (Note 23 C1)	2,467,000	4,084,000	1,645,106	3,959,542
NUH Health Research Endowment Fund (Note 23 C2)	7,193,000	3,000,000	2,250,257	3,000,000
VIVA Paediatric Oncology Fund (Note 23 C3)	12,270,000	23,744,000	2,275,146	22,146,568
VIVA Education and Research Fund (Note 23 C4)	780,000	1,286,000	-	1,130,543
Subtotal	22,710,000	32,114,000	6,170,509	30,236,653
Total	78,172,993	45,065,588	36,887,793	43,188,241

## (A) Specific Donations Received under the Charity as Donation Income

The Charity received donations for certain designated funds. These donations were reflected in the financial statements of the Charity as donation income. Subsequently, the Charity donated these to the designated fund managed by the Community Partners. The donated amounts were reflected in the financial statements of the Charity as expenditure incurred for charitable activities. The details of the funds which the amounts expended are not reflected in the financial statements of the Charity are as follows:

### (A1) VIVA-NUS Centre for Translational Research in Acute Leukaemia (“CentRAL”)

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	(217,610)	-	244,067	-
- Add/(Less):				
- Donation received	-	-	1,264,052	-
- Other income	254,593	-	4,706	-
- Expenditures	(35,190)	-	(1,730,435)	-
Balance at 31 December	1,793	-	(217,610)	-
<b>Total Funds Raised by the Charity</b>	<b>8,026,692</b>	<b>-</b>	<b>7,772,099</b>	<b>-</b>

The funds were donated by the Charity to the National University of Singapore to support the advancement of education and research with the establishment of CentRAL, a state-of-the-art leukaemia research and diagnostic facility with the key objective of improving the cure rates and quality of life of patients with leukaemia and haematologic cancer in Singapore and the Asia region, through accurate leukaemia classification, prediction and determination of treatment response. During the financial year ended 31 December 2019, the Charity received S\$1.26 million of donations from Singapore Tote Board. As at 31 December 2019, these amounts have been subsequently donated by the Charity to CentRAL.

### (A2) VIVA-Mr Goh Hup Jin Fund for Translational Research in Acute Leukaemia (“CentRAL”)

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	-	-	-	-
- Add/(Less):				
- Donation received	1,300,000	-	-	-
Balance at 31 December	1,300,000	-	-	-
<b>Total Funds Raised by the Charity</b>	<b>1,300,000</b>	<b>-</b>	<b>-</b>	<b>-</b>

The funds were donated by Mr Goh Hup Jin to support the advancement of education and research at CentRAL. As at 31 December 2020, these amounts have been subsequently donated by the Charity to CentRAL.



## (A3) Cancer Immunotherapy

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	-	-	-	-
- Less:				
- Expenditures	-	-	-	-
Balance at 31 December	-	-	-	-
<b>Total Funds Raised by the Charity</b>	<b>1,000,000</b>	<b>-</b>	<b>1,000,000</b>	<b>-</b>

The funds were donated by the Charity to Yong Loo Lin School of Medicine, National University of Singapore, to fund cancer immunotherapy clinical research, specifically to support clinical trials of novel therapies based on immune cells for children and adults with drug resistant cancer. During 2014, a S\$1 million donation was made to NUS by the Charity.

## (B) Specific Donations Co-funded by the Charity and Community Partners

The Charity and Community Partners raised funds separately where the contributions by donors were designated for specific purposes. The Charity donations were reflected in the financial statements of the Charity as donation income. Subsequently, when the Charity donated these to the designated funds managed by the Community Partners, the amounts were reflected in the financial statements of the Charity as an expenditure incurred for charitable activities. The details of the funds which the amounts expended were not reflected in the financial statements of the Charity are as follows:

## (B1) VIVA-KKH Childhood Brain and Solid Cancers Programme

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	5,312,631	12,951,588	7,071,425	10,951,528
<u>Add/(Less):</u>				
- Additional matched grant	-	-	-	2,000,060
- Expenditures	(294,634)	(1,588)	(1,758,794)	-
Balance at 31 December	5,017,997	12,950,000	5,312,631	12,951,588
<b>Total Funds Raised by the Charity</b>	<b>13,257,349</b>	<b>12,951,588</b>	<b>13,257,349</b>	<b>12,951,588</b>

The funds were donated by the Charity to KKH Health Fund (formerly known as KKH Health Endowment Fund) used for the advancement of the treatment and cure for children with brain and solid tumours in Singapore and the Asia Pacific region under the VIVA-KKH Childhood Brain and Solid Cancers Programme. This programme focuses on four areas of childhood brain and solid cancers in clinical care, translational research, registry-based population science, and collaborative education and training. During the previous financial year ended 31 December 2019, a S\$2 million donation was made to VIVA-KKH by the Charity.

## (C) Specific Donations Paid Directly to Community Partners as Beneficiaries

The Charity raised funds for the following four projects, where the contributions by donors were designated for specific purposes and paid directly to the Community Partners. The details of the funds which the donations and the amounts expended below are not reflected in the financial statements of the Charity are as follows:

### (C1) NUS Children Cancer Centre Fund (“CCCF”)

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	1,645,106	3,959,542	1,623,461	3,840,136
<u>Add/(Less):</u>				
- Investment income	17,682	-	15,814	242,350
- Other income	3,109	-	6,582	-
- Expenditure	(189,947)	(168,793)	(751)	(122,944)
- Investment loss		(91,542)		
- Transfer to unrestricted endowment		(571,110)		
- Transfer to unrestricted non-endowment fund		(597,458)		
Balance at 31 December	1,475,950	2,530,639	1,645,106	3,959,542
<b>Total Funds Raised by the Charity</b>	<b>2,488,622</b>	<b>4,084,512</b>	<b>2,467,831</b>	<b>4,084,512</b>

The funds were donated to the National University of Singapore – Children Cancer Centre Fund to establish a children’s cancer centre, now known as the VIVA-University Children’s Cancer Centre (“VUC3”) at the National University Hospital which will be the centre of excellence for the treatment and cure of childhood cancer particularly leukaemia; the training and hiring of doctors, nurses, technical and administrative personnel from Singapore and the region; clinical and translational research; cellular therapy and stem cell transplantation. The funding is by VIVA Foundation and by Singapore Totalisator Board.

### (C2) NUH Health Research Endowment Fund (“HREF”)

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	2,250,257	3,000,000	2,201,187	3,000,000
<u>Add/(Less):</u>				
- Other income	43,995	-	49,098	-
- Expenditure	(24)	-	(28)	-
Balance at 31 December	2,294,228	3,000,000	2,250,257	3,000,000
<b>Total Funds Raised by the Charity</b>	<b>7,237,009</b>	<b>3,000,000</b>	<b>7,193,014</b>	<b>3,000,000</b>

The funds were donated to the National University Hospital to establish the Mrs Lee Kong Chian Memorial Chair, for Director of Advanced Clinical and Translational Research for Childhood Leukaemia and Cellular Therapy under the VIVA Children's Cancer Programme. The donation of S\$3 million was received from the Lee Foundation, via the VIVA Foundation and was matched by the Ministry of Health with S\$3 million in two payments received on December 2006 and March 2007. The money was used as a bridging loan to support the setting up of the VUC3.

### (C3) VIVA Paediatric Oncology Fund ("VPOF")

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	2,275,146	22,146,568	2,981,836	21,416,457
<u>Add/(Less):</u>				
- Investment income	15,512	-	-	1,349,821
- Other income	-	-	38,095	-
- Expenditure	(947,619)	(953,505)	(744,785)	(619,710)
- Investment Loss	-	(498,820)	-	-
- Transfer to unrestricted endowment fund	-	(3,396,110)	-	-
- Transfer to unrestricted non-endowment fund	-	(3,578,497)	-	-
Balance at 31 December	<u>1,343,039</u>	<u>13,719,636</u>	<u>2,275,146</u>	<u>22,146,568</u>
<b>Total Funds Raised by the Charity</b>	<b><u>12,285,705</u></b>	<b><u>23,743,824</u></b>	<b><u>12,270,193</u></b>	<b><u>23,743,824</u></b>

The VIVA Paediatric Oncology Fund has been established with an expendable gift of S\$12 million dollars from the Goh Foundation with a matching grant from the Singapore Government to Yong Loo Lin School of Medicine, NUS. The fund is used to advance paediatric oncology including, but not limited to, supporting the VIVA University Children's Cancer Centre and St. Jude VIVA Children's cancer programme. This programme aims to expand the services in paediatric oncology at the National University Health System and to establish for strategic research programmes in the following fields: 1) Bone Marrow Transplant, 2) Childhood Leukaemia, 3) Bone Cancer, 4) After-Completion-of-Therapy and to set up a professorship in paediatric oncology.

#### (C4) VIVA Education and Research Fund (“VERF”)

	2020		2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	-	1,130,543	-	1,106,611
<u>Add/(Less):</u>				
- Investment income	-	-	-	69,468
- Investment loss	-	(26,240)		
- Transfer to unrestricted endowment fund	-	(160,720)		(45,536)
- Transfer to unrestrict- ed non-endowment fund	-	(167,368))	--	-
Balance at 31 December	-	776,215	-	1,130,543
<b>Total Funds Raised by the Charity</b>	<b>780,000</b>	<b>1,286,654</b>	<b>780,000</b>	<b>1,286,654</b>

The funds were donated by the Charity to the National University of Singapore, Department of Paediatrics in support of education, training and research in paediatric oncology specifically through projects that are part of the VIVA Children’s Cancer Programme and income and expenses for the Annual St. Jude VIVA Forum in paediatric oncology. In 2013, the fund was closed and the balance of S\$78,448 was refunded to the Charity.



# CODE OF GOVERNANCE

## COMPLIANCE WITH CODE OF GOVERNANCE

VIVA Foundation constantly works towards compliance with the Charities Act, Charities (Institutions of Public Character) Regulations, Charities Accounting Standards, the Code of Governance for Charities and IPCs and the Personal Data Protection Act, and take steps to address and resolve weakness/es where appropriate.

## MANAGING CONFLICT OF INTEREST

VIVA Foundation has in place a policy relating to the management and avoidance of conflict of interests. All Members, Directors and staff are required to sign the prescribed Declaration of Conflict of Interest form when they are appointed and thereafter annually or whenever there is any material change in the information contained in their respective Declarations.

## ONLINE GOVERNANCE EVALUATION CHECKLIST (GEC) via CHARITY PORTAL

VIVA Foundation has been submitting the GEC annually via the Charity Portal. These are also available on VIVA's website at [www.viva.sg](http://www.viva.sg).

## RESERVES POLICY

VIVA Foundation has set aside a reserve of \$1 million to provide financial stability and resources for the development of its principal activities. The Board will periodically review the amount of reserves that are required to ensure adequacy in fulfilling the Foundation's obligations.

## SALARIES AND RELATED COSTS

No Directors received any remuneration. During the financial year 2018, no staff personnel received an annual remuneration of \$100,000.00 and above. No staff is involved in setting his/her own remuneration.

VIVA discloses that there is no paid staff, being a close member of the family belonging to the Executive Head or a governing board member of the charity, who has received remuneration exceeding \$50,000 during the financial year.

## REELECTION OF DIRECTORS

Board of Directors appointed during the financial year were re-elected by the Members at the Annual General Meeting.

VIVA Foundation does not have term limits of Directors/Members as the Board believes that continued contribution by each Director provides benefits to the foundation. Each Director's integrity is not compromised by the long period of service.

The Board decided, with the Members' approval, that Directors who serve in the Board for more than 10 years are retained. All Directors who are over the age of 70 years were re-appointed to hold office until the conclusion of the next Annual General Meeting of the Company pursuant to Section 153(6) of the Companies Act, Chapter 50.

## BOARD MEMBERS ATTENDANCE AT MEETINGS

During the year, three (3) meetings were held - 2 Ordinary Board Meetings and 1 Annual General Meeting. A Director who is unable to attend any meeting in person may participate via teleconference.

The Board is satisfied that each Director is committed towards fulfilling the mission of VIVA Foundation. This is evidenced by their respective valuable contributions in many ways despite not attending some or all of the meetings during the year due to prior commitments.

## INTERNAL CONTROL AND RISK MANAGEMENT MEASURES

The Board assumes overall responsibility and is fully committed on maintaining a sound system of internal control and risk management that provide reasonable assurance of effective operations and statutory compliance in accordance with the Code of Governance and Charity Accounting Standards.

The Board ensures that there is a sound internal control policies and procedures in place.

The Board constantly reviews, taking into account changes in the regulatory and statutory, these policies and procedures to ensure adequacy and effectiveness.

The Board has also put in place a risk management policy. One of these policies is the implementation of internal controls as part of the day to day operations.

#### **VOLUNTEER MANAGEMENT**

VIVA discloses that there are volunteer management processes in place for volunteers.

## BOARD OF DIRECTORS

In 2020, two (2) Ordinary Board Meetings and one (1) Annual General Meeting were held. The Executive Committee\* actively oversees the business of VIVA. The VIVA Board of Directors, comprising 12 Directors, serves pro-bono and ensures that VIVA's mission and vision are met.

### EXECUTIVE COMMITTEE



**Mrs Jennifer Yeo**  
**(Mdm Leong Lai Peng)**  
Founder and Chairman

Senior Consultant, RHTLaw  
Advocate & Solicitor, Singapore  
Solicitor, England & Wales

*Appointed on 6 Feb 2006*



**Mdm Kuok Oon Kwong**  
Vice-Chair

Chairman, National Healthcare  
Group  
Director, Shangri-La Hotel Ltd  
Singapore

*Appointed on 9 Nov 2007*



**Mr Christopher Wilson**  
Co-Founder, Water and  
Healthcare Foundation

*Appointed on 15 Jan 2015*



**Ms Shulamite N K Khoo**  
Independent Non-Executive  
Director, Kerry Logistics  
Network Limited

*Appointed on 1 May 2018*



**Ms Cynthia Phua**  
Management Consultant  
Former Singapore Member of  
Parliament (2001-2011)

*Appointed on 17 Jun 2019*

## BOARD OF DIRECTORS



**Ms Tan Bee Lan**  
President,  
Columbia China

*Appointed on 1 Aug 2014*



**Mr Gilbert Cheah**  
Managing Director,  
Catalyst Communications

*Appointed on 1 Mar 2016*



**Ms Diaan-Yi Lin**  
Senior Partner,  
McKinsey Singapore

*Appointed on 7 Apr 2020*



**Mr Martino Tan**  
Managing Editor,  
Mothership.sg

*Appointed on 1 May 2018*



**Mdm Yeong Yoon Ying**  
Director (Special Duties),  
Ministry of Communications  
and Information

*Appointed on 18 Jan 2019*



## EXTERNAL ADVISORY BOARD

VIVA's External Advisory Board (EAB) is made up of an international panel of renowned doctors from the global field of cancer care and research. The VIVA Board of Directors seeks strategic advice and views from the EAB with regards to programmes and projects.

The EAB meets in Singapore once a year. At other times of the year, the Board would also call on the EAB for their expert views and thoughts when necessary.



**Dr. Ching-Hon Pui, MD**  
Chairman

American Cancer Society Professor  
Chair, Department of Oncology  
Co-Leader, Hematological  
Malignancies Program  
Fahad Nassar Al-Rashid Chair of  
Leukemia Research  
Director, China Region,  
St. Jude Global, St. Jude Children's  
Research Hospital  
Memphis, Tennessee, USA

*Appointed on 19 Dec 2006*



**Dr Rupert Handgretinger, MD**  
Member

Professor and Chairman,  
Department of General Paediatrics  
and Hematology / Oncology  
Children's University Hospital  
Tuebingen, GERMANY

*Appointed on 7 Dec 2006*



**Dr Edward Holmes, MD**  
Member

President and CEO, Sanford  
Consortium for Regenerative  
Medicine  
Senior Fellow, A\*STAR Advisor  
National Research Foundation  
SINGAPORE

*Appointed on 30 Nov 2006*



**Prof Anjo Veerman, MD**  
Member

Professor Emeritus, Paediatrics  
Vrije Universiteit University  
Medical Center  
Amsterdam, THE NETHERLANDS

*Appointed on 18 Dec 2006*



**Prof Wing Leung, MBBS, PhD**  
Member

Director and Senior Consultant,  
Paediatric Bone Marrow Transplant  
and Cell Therapy Centre  
Senior Consultant, Haematology  
Oncology Service, KK Women's and  
Children's Hospital  
Professor, Duke-NUS Medical  
School  
Chair, TCL-CCF Professorship  
SINGAPORE

*Appointed on 25 Feb 2020*



## TO A HOLISTIC FUTURE FOR SURVIVORS

Since VIVA began in 2006, we have been working towards our mission to save more lives for children with cancer through excellence in research, medical care, and education—embarking on impactful collaborations and exchanges that have paid dividends in improving survival rates for childhood cancer patients.

While our work in these areas continues, VIVA is also moving towards taking a holistic approach towards cancer care by introducing programmes that focus on the physical, mental, and emotional health and well-being of patients and survivors.

We will be launching the VIVA Life Programme, which will bring together collaborators to provide holistic survivorship care for those affected by childhood cancers. It is our belief that care does not end upon discharge from treatment centres, but rather, children and families affected by childhood cancer continue to need care and support in order to enable the child to not just survive, but thrive.

**With love,**  
VIVA Foundation for Children with Cancer



# Thank You!

VIVA would like to express our warmest gratitude to all our donors, volunteers and supporters who contributed to our mission in 2020.

**We could not have done this without you.**





[bit.ly/donate2viva](https://bit.ly/donate2viva)

# Help us rewrite the future of kids with cancer.

Donate to the **VIVA Foundation**  
for Children with Cancer today.

[bit.ly/donate2viva](https://bit.ly/donate2viva)



Scan the QR code  
with your preferred  
banking app to  
donate instantly!

## Connect with Us

8 Sinaran Drive  
#03-01 Novena Specialist  
Centre  
Singapore 307470

☎ 6694 3370  
✉ [enquiry@viva.sg](mailto:enquiry@viva.sg)

[www.viva.sg](https://www.viva.sg)

f in  
[@VivaFoundation](https://www.instagram.com/VivaFoundation)